Antios Therapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases. With our lead oral candidate (ATI-2173), we are aiming to develop a cure for chronic hepatitis B.
Hepatitis B (HBV) is a virus of the liver transmitted through contact with blood or other body fluids of an infected individual. An astounding 1 out of 3 people have been infected worldwide. Many have no symptoms and either recover or develop silent chronic liver disease.
Approximately 5% of those with acute HBV develop chronic HBV (over 250 million individuals worldwide), leading to scarring of the liver, liver cancer, and can be fatal if left untreated. Approximately 10% of those with chronic HBV are aware of their infection. With current treatment, only 5 - 10% of those chronically infected can be cured, meaning that most patients require lifelong treatment to control their infection.
At Antios, we are committed to developing a functional cure for this global health epidemic.
